Circulating Mutant Dna to Assess Tumor Dynamics
DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. We apply a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in body samples of patients. Measurements of ctDNA can be used to reliably monitor tumor dynamics in subjects with cancer, especially those who are undergoing surgery or chemotherapy. This personalized genetic approach can be generally applied.
DIEHL FRANK [DE]; DIAZ LUIS [US]; KINZLER KENNETH W [US]; VOGELSTEIN BERT [US]; SCHMIDT KERSTIN [US]
Type of Offer:
« More Biotech Patents